The projected annual revenue for Mayne Pharma Group is 428MM, an increase of 132.88%. The projected annual non-GAAP EPS is -0.56.
If analysts give a stock an overweight rating, they expect the stock to outperform its industry in the market. Analysts may give a stock an overweight recommendation due to a steady stream of positive news, good earnings, and raised guidance.
As of August 31, 2023, the average one-year price target for Mayne Pharma Group is 4.43. The forecasts range from a low of 3.84 to a high of $5.04. The average price target represents a decrease of 6.73% from its latest reported closing price of 4.75
WILSONS Maintains Mayne Pharma Group (ASX:MYX) Overweight Recommendation
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$5.12 |
Change
-0.130(2.48%) |
Mkt cap ! $417.6M | |||
| Open | High | Low | Value | Volume |
| $5.17 | $5.18 | $5.11 | $135.3K | 26.32K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 240 | $5.11 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $5.12 | 515 | 2 |
View Market Depth
| Last trade - 10.55am 29/07/2025 (20 minute delay) ? |
| MYX (ASX) Chart |